These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 84343)

  • 1. Human urinary bladder carcinoma cell line (T24): immunological studies and search for oncornavirus in T24 cell population and derived clones.
    Bubeník J; Asfahani A; Sherif M; El Ridi R; Mach O; Machácková M; Jandlová T; Símová J; Hanus M; Hradec E; Malkovský M
    Neoplasma; 1978; 25(5):513-22. PubMed ID: 84343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of antigens on transitional cell carcinoma with a xenogeneic antiserum.
    Bloom ET
    Natl Cancer Inst Monogr; 1978 Dec; (49):57-8. PubMed ID: 86168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
    Hermann GG; Zeuthen J; Claësson MH
    Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cellular immune response of bladder tumor patients: effects of aging on cytotoxic activity against T24].
    Kato M
    Hinyokika Kiyo; 1988 Aug; 34(8):1363-9. PubMed ID: 3195404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro generation of cytotoxic lymphocytes by tumor extracts of transitional cell carcinoma.
    Morales A
    Natl Cancer Inst Monogr; 1978 Dec; (49):173-4. PubMed ID: 748769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients.
    Spina CA; Dorey F; Vescera C; Brosman S; Fahey JL
    Cancer Res; 1981 Nov; 41(11 Pt 1):4324-30. PubMed ID: 6458353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated and spontaneous lymphocyte-mediated cytotoxicity against cell lines derived from human urothelium.
    Vilien M
    Dan Med Bull; 1985 Aug; 32(4):199-218. PubMed ID: 3899526
    [No Abstract]   [Full Text] [Related]  

  • 10. Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2.
    Bubeník J; Kieler J; Tromholt V; Steven K; Indrová M; Toulcová A
    Folia Biol (Praha); 1986; 32(3):183-94. PubMed ID: 3488923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transitional cell carcinoma: lymphocyte-mediated cytotoxicity.
    Troye M; Pape GR
    Natl Cancer Inst Monogr; 1978 Dec; (49):85-7. PubMed ID: 311895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human neutrophil-mediated cytotoxicity to tumor cells.
    Gerrard TL; Cohen DJ; Kaplan AM
    J Natl Cancer Inst; 1981 Mar; 66(3):483-8. PubMed ID: 6937705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specificity of in vitro cellular cytotoxicity against transitional cell carcinoma cell line T-24.
    Catalona WJ; Oldham RK; Djeu JY; Herberman RB; Cannon GB
    Surg Forum; 1975; 26():122-4. PubMed ID: 56048
    [No Abstract]   [Full Text] [Related]  

  • 15. Human bladder cancer cell-surface antigens recognized by murine monoclonal antibodies raised against T24 bladder cancer cells.
    Masuko T; Abe J; Yagita H; Hashimoto Y
    Jpn J Cancer Res; 1985 May; 76(5):386-94. PubMed ID: 3924712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
    Mizutani Y; Okada Y; Yoshida O; Bonavida B
    Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary studies of sera and urine from patients with bladder cancer.
    Hollinshead AC
    Natl Cancer Inst Monogr; 1978 Dec; (49):193-7. PubMed ID: 219366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood lymphocyte subsets in urinary bladder carcinoma patients.
    Gaafar T; Lotfy M; el Ridi R
    Arch Immunol Ther Exp (Warsz); 1991; 39(5-6):511-7. PubMed ID: 1726772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-mediated tumour immunity in patients with transitional cell carcinoma of the urinary bladder.
    Bubeník J
    Int Urol Nephrol; 1975; 7(4):297-302. PubMed ID: 1107249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.